| P50 | author | Joseph R Arron | Q61147913 |
| | Bradley T Scroggins | Q114883608 |
| P2093 | author name string | Thomas A Wynn | |
| | Thirumalai R Ramalingam | |
| | Eun Joo Chung | |
| | Jason A Horton | |
| | Deborah E Citrin | |
| | Su I Chung | |
| | Kathryn E Hudak | |
| | Ayla O White | |
| P2860 | cites work | Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial | Q38396364 |
| | Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial | Q38526067 |
| | Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma | Q39792840 |
| | Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. | Q39994240 |
| | Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial | Q40445632 |
| | Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. | Q40672713 |
| | Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production | Q40849898 |
| | Requirement for IL-13 independently of IL-4 in experimental asthma | Q41881960 |
| | Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). | Q42101278 |
| | Irradiation induces a biphasic expression of pro-inflammatory cytokines in the lung. | Q42464320 |
| | Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation | Q42489472 |
| | IL-13 fusion cytotoxin ameliorates chronic fungal-induced allergic airway disease in mice | Q43803704 |
| | IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent | Q44007756 |
| | Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study | Q44799322 |
| | Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent | Q44826352 |
| | Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. | Q44937602 |
| | Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms | Q45736589 |
| | Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma | Q45802993 |
| | IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome | Q46046480 |
| | Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. | Q46784009 |
| | Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation | Q46948858 |
| | Target cells in radiation pneumopathy | Q47232808 |
| | Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis | Q49163938 |
| | Characterization of the interaction between interleukin-13 and interleukin-13 receptors | Q28248430 |
| | IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts | Q28267624 |
| | IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis | Q28285105 |
| | Interleukin-13: central mediator of allergic asthma | Q28291712 |
| | Macrophage activation and polarization: nomenclature and experimental guidelines | Q29620642 |
| | Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies | Q30957004 |
| | Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. | Q33799732 |
| | TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? | Q33913350 |
| | Lebrikizumab treatment in adults with asthma | Q34205683 |
| | Pulmonary radiation injury | Q34421890 |
| | Chronic airway hyperreactivity, goblet cell hyperplasia, and peribronchial fibrosis during allergic airway disease induced by Aspergillus fumigatus | Q35745429 |
| | Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention | Q36166696 |
| | Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response | Q36370595 |
| | Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor alpha2 in vivo | Q37163250 |
| | Role of type II pneumocyte senescence in radiation-induced lung fibrosis | Q37209545 |
| | A novel and sensitive ELISA reveals that the soluble form of IL-13R-alpha2 is not expressed in plasma of healthy or asthmatic subjects | Q37221291 |
| | Radiation Pulmonary Toxicity: From Mechanisms to Management | Q37777878 |
| | Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. | Q37820920 |
| | Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. | Q52543547 |
| | Allergy-driven alternative splicing of IL-13 receptor alpha2 yields distinct membrane and soluble forms. | Q54570911 |
| | Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol | Q73042279 |
| | Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells | Q73827875 |
| | IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs | Q77899629 |
| | IL-13 receptor alpha2 promotes epithelial cell regeneration from radiation-induced small intestinal injury in mice | Q79871786 |
| | Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies | Q81471173 |
| | Differences in expression, affinity, and function of soluble (s)IL-4Ralpha and sIL-13Ralpha2 suggest opposite effects on allergic responses | Q81550256 |
| | Enhanced expression of the decoy receptor IL-13Ralpha2 in macrophages of Schistosoma japonicum-infected mice | Q84497430 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 39714 | |
| P577 | publication date | 2016-12-22 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | IL-13 is a therapeutic target in radiation lung injury | |
| P478 | volume | 6 | |